MDLinx September 19, 2024
Meghan McCallum

Key Takeaways

  • GLP-1 receptor agonists like Ozempic show promise not only in treating type 2 diabetes and obesity but also in potentially addressing other health issues, such as addiction and cognitive decline.

  • While GLP-1s represent a revolutionary advancement in treatment, barriers such as insurance coverage and access still exist.

  • There is a...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Pharma / Biotech, Physician, Provider
109 hospitals receiving new Medicare-backed residency slots
STAT+: UnitedHealth pays its own physician groups considerably more than others, driving up consumer costs and its profits
AI Robot Scanner as Good as Rheumatologists at Assessing RA
Senators urge Congress to avert Medicare physician pay cut
New study offers insights into reliable Alzheimer's diagnosis

Share This Article